secwatch.observer — SEC 8-K summary
======================================

Issuer:     Kairos Pharma, LTD. (KAPA)
CIK:        0001962011
Form:       8-K
Filed at:   2025-04-28T23:59:59+00:00
Accession:  0001641172-25-006504
Event type: other_material
Sentiment:  neutral
Materiality: 0.55
Item codes: 4.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Kairos Pharma replaces auditor Marcum with Weinberg; 2023 report had going concern
--------------------------------------------------------------------------------

- Audit committee dismissed Marcum LLP and appointed Weinberg & Company effective April 23, 2025.
- Marcum's 2023 audit report included a going concern uncertainty; 2024 report had no such modification.
- No disagreements on accounting principles or audit scope occurred during Marcum's tenure.
- Material weaknesses in internal control over financial reporting were disclosed for 2024 and 2023.
- Marcum provided a letter agreeing with the statements in this 8-K filed as Exhibit 16.1.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1962011/000164117225006504/0001641172-25-006504-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1962011/000164117225006504/form8-k.htm
  HTML page:      https://secwatch.observer/filing/0001641172-25-006504

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer